Company Cash and Securities Total $452.4M, Expected to Last into H1 2029
As of March 31, the company had cash, cash equivalents and marketable securities totaling $452.4M, expected to provide cash runway into the first half of 2029. "Recent strategic momentum in CML validates a remaining unmet need and a compelling long-term opportunity. Against this backdrop, we remain focused on execution as we prepare to initiate the Phase 3 pivotal trial of ELVN-001 in the second half of 2026," said CEO Rick Fair. "Based on the Phase 1 data generated to date, we believe ELVN-001 has the potential to be the best-in-class ATP-competitive inhibitor in CML and that it is positioned strongly to compete across all lines of therapy."
